Abstract 5085
Background
The EORTC 1325-MG/Keynote 054 trial demonstrated prolonged recurrence-free survival with adjuvant pembrolizumab compared to placebo (hazard ratio = 0.57; P < 0.001. Eggermont et al, NEJM, 2018). Incidence of adverse events grades 3 or higher related to treatment were higher in the pembrolizumab arm (14.7%) than the placebo arm (3.4%). Here we report results from the health-related quality of life (HRQoL) exploratory endpoint.
Methods
A total of 1019 patients with histologically confirmed, cutaneous melanoma metastatic to a lymph node, classified as stage IIIA, IIIB or IIIC were randomized after complete resection to receive 200 mg pembrolizumab (514 patients) or placebo (505 patients). Treatment was administered every 3 weeks for 1 year, or until disease recurrence or unacceptable toxicity. All enrolled patients were required to complete a HRQoL questionnaire at baseline and every 12 weeks (during 2 years after randomization). The primary HRQoL outcome was global health/QoL (GHQ) as measured by the EORTC QLQ-C30. All other scales from this questionnaire were secondary. Scores were compared according to the average score per patient overall, during treatment and after treatment.
Results
HRQoL compliance was >90% at baseline, >70% during the first year and >60% thereafter for both arms. Data attrition limited the analyses to week 84 (19 months). Baseline GHQ scores were similar between arms at 77 points and remained stable over time. The average GHQ score was 2.2 points (95% CI: 4.3-0.2), 1.1 points (95% CI: 3.2 - -0.9) and 2.2 points (95% CI: 4.8 - -0.4) lower in the pembrolizumab arm compared to placebo for the average overall, during and after treatment respectively. These differences are within 5 point clinical relevance threshold for the QLQ-C30. Results from the secondary scales revealed a similar pattern with scores stable over time and treatment differences never reaching the 5 point threshold.
Conclusions
Pembrolizumab maintains health-related quality of life compared to placebo, when given as adjuvant therapy for patients with resected high-risk stage III melanoma.
Clinical trial identification
EudraCT: 2014-004944-37; NCT02362594.
Legal entity responsible for the study
Merck.
Funding
Merck.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract